Belite Bio (BLTE) Q4 2025 earnings summary

Executive summary

• Achieved positive topline results in the pivotal Phase 3 DRAGON trial for tinlarebant in Stargardt disease (STGD1), meeting primary efficacy endpoints with a 35.7% reduction in lesion growth rate and supporting a planned NDA submission in Q2 2026.

• Completed enrollment in the DRAGON II study for STGD1 (72–75 subjects) and the Phase 3 PHOENIX trial in geographic atrophy (GA) (430–530 subjects).

• Raised $402 million through a public offering, closing the year with $772.6 million in cash, cash equivalents, and U.S. Treasury holdings.

• Preparing for a transformative 2026 with NDA submission for tinlarebant and ongoing commercialization build-out.

Financial highlights

• Q4 2025 GAAP net loss was $25.3 million (vs. $10.1 million in Q4 2024); non-GAAP net loss was $13.6 million (vs. $5.9 million).

• Full-year 2025 GAAP net loss was $77.6 million (vs. $36.1 million in 2024); non-GAAP net loss was $38.7 million (vs. $27.2 million).

• R&D expenses for 2025 were $45.4 million (up from $29.9 million in 2024); SG&A expenses were $38.9 million (up from $10.1 million).

• Q4 2025 GAAP total operating expenses: $28.1 million, up from $11.5 million in Q4 2024.

• Cash, cash equivalents, and U.S. Treasury holdings totaled $772.6 million at year-end 2025.

Outlook and guidance

• NDA submission for tinlarebant in STGD1 planned for Q2 2026, with commercialization launch targeted for Q1 2027.

• Commercialization build-out underway, with key leadership hired and teams being established.

• Estimated $150 million in R&D and NDA-related costs and $200–$250 million for commercialization over the next three years.

• Pricing guidance suggests rare disease drug pricing in the US averages $350,000, with expectations to potentially exceed this.

• Interim analysis planned for the PHOENIX trial in GA.